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Abstract
Purpose To study the changes in serum ferritin levels in
lamivudine (LAM)-treated patients with chronic hepatitis
and liver cirrhosis type B and determine whether successful
treatment with LAM results in a reduction of serum ferritin
levels.
Methods Thirty patients with chronic hepatitis B virus
(HBV) infection were followed prospectively during their
treatment with LAM for 12 months. Serum HBV DNA,
ferritin levels, and emergence of YMDD mutants were
monitored. A case of severe liver cirrhosis with hepatic
hemosiderosis that was treated successfully with LAM also
is shown as a representative case.
Results Serum alanine aminotransferase and ferritin lev-
els decreased signiﬁcantly more in the patients treated with
LAM without YMDD mutants (n = 23) than those with
mutants (n = 7). Hepatic hemosiderosis along with serum
iron markers improved greatly in the representative patient.
Conclusion Successful treatment with LAM may reduce
serum ferritin levels and improve hepatic siderosis in a
subset of patients with chronic HBV infection.
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Introduction
Hepatitis B virus (HBV) is one of the major causes of liver
cirrhosis and hepatocellular carcinoma (HCC) [1–3]. Pro-
gression of liver disease is caused by inﬂammation due to
active replication of HBV. It is thus important to imple-
ment antiviral therapy against chronic hepatitis B to
minimize liver damage [4, 5].
Lamivudine (LAM), the ﬁrst-licensed anti-HBV drug in
Japan, has been shown to be effective in inhibiting HBV
replication [6, 7]. A signiﬁcant improvement in necroin-
ﬂammation activity has been shown following LAM
treatment [8]. However, deterioration of the clinical course
results from the emergence of YMDD mutants during
treatment [9, 10]. Frequently this may cause an acute ﬂare
of alanine aminotransferase (ALT), probably attributable to
the immune response to the newly developed variants.
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DOI 10.1007/s12072-008-9084-zIronoverloadisobservedfrequentlyintheliversofpatients
withchronicviralhepatitis[11].Ithasbeensuggestedthatiron
overload may facilitate virus replication in hepatocytes and
virus-infected liver cells may tend to accumulate iron. In
addition,cirrhosisalonemaycauseironoverloadandthisstate
is common in patients with end-stage liver cirrhosis [12, 13].
Hepatic siderosis may improve with successful interferon
treatment of patients with chronic hepatitis C [14].
Liu et al. [15] reported that the LAM treatment could
reduce the serum ferritin levels in patients with chronic
HBV infection. In this study, we show that patients who
were treated successfully with LAM without the emer-
gence of YMDD mutants had a clear reduction in their
serum ferritin levels. We also describe a patient with severe
hepatic siderosis, accompanying end-stage liver cirrhosis
due to HBV infection, who showed a reduction of iron
accumulation following successful treatment with LAM.
Materials and methods
Patients
We studied prospectively 30 patients with chronic HBV
infection.Thepatients’characteristicsareshowninTable 1.
Liver biopsywas performed in21 patients (70%). Six (20%)
had histologically proven liver cirrhosis (F4). All patients
received LAM treatment for more than 1 year and the ﬁrst
12 months of treatment were analyzed. Individual
biochemicaldataandserumHBVDNAlevelswereobtained
each month. Detection of YMDD mutants was carried out 6
and12 monthsaftertheinitiationoftreatment.Inadditionto
these patients, we present a single case with liver cirrhosis
type B in whom successful treatment by LAM brought a
marked improvement of serum iron markers.
Methods
HBV genotype and precore and core promoter mutations
were detected using a commercial kit (Genome Science
Laboratory, Japan). HBV DNA concentrations were
determined using the transcription-mediated ampliﬁcation
(TMA) test. YMDD mutants were detected by a mini-
sequencing method (Genome Science Laboratory, Japan).
Statistical analysis
The results were expressed as means ± standard deviation.
Student’s t test was used for statistical analysis asappropriate.
A P value of\0.05 was considered statistically signiﬁcant.
Results
Seven (7/30, 23%) patients had developed YMDD mutants
at 12 months after the initiation of LAM treatment. Serum
ALT levels were signiﬁcantly higher in patients with
mutants at 12 months (P B 0.01) (Fig. 1a). All seven
patients with mutants had an elevation of ALT levels that
showed breakthrough hepatitis. All 23 patients without
mutants had HBV DNA levels below the detection limit
(\3.7 LGE/ml), whereas seven patients with mutants had
detectable HBV DNA levels at 12 months (Fig. 1b). Serum
ferritin levels decreased at 6 months of treatment, along
with a decrease of ALT and HBV DNA levels. They
increased in patients in whom mutants appeared along with
an increase of ALT and HBV DNA values, whereas they
continued to decrease in patients without mutants
(P\0.01 at 12 months after the treatment) (Fig. 1c).
We analyzed serum iron and unsaturated iron-binding
capacity (UIBC) levels in the course of LAM treatment
(Table 2).Althoughtherewerenosigniﬁcantchangesinserum
iron levels between each time point after the initiation of
treatment, irrespective of the appearance of mutants, the mean
UIBC value at 12 months posttreatment was signiﬁcantly
higher than pretreatment in patients without mutants
(P\0.05).
Case
A 55-year-old Japanese man had been followed for chronic
HBVinfectionsince1988.Interferontherapywasineffective
Table 1 Patient proﬁle and laboratory data at commencement of
lamivudine therapy in 30 patients with chronic hepatitis B or cirrhosis
Demographic data
Number 30
Sex, M/F 24/6
Age, years 45(26–67)
Family history of HBV carrier 14 (45%)
Laboratory data
Serum alanine aminotransferase, IU/l 161 (31–835)
Serum albumin, g/dl 4.1(2.5–5.1)
Platelet count, X10
4/mm
3 13.7(4.4–23.1)
Serum ferritin, ng/ml 163(15–602)
Virological data
HBV DNA, LGE/ml 6.8(3.9–[8.7)
HBeAg(+/-) 18/12
Genotype(C:B) 29/1
Precore(wild/mutant/mixture) 14/9/7
Core promoter(wild/mutant/n.d) 3/25/2
Histological ﬁndings
Stage (F1/F2/F3/F4/n.d)
a 6/5/4/6/9
Data are expressed as median (range). n.d (not detected)
a Stage of chronic hepatitis by Desmet et al. [26]
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123and the disease progressed to liver cirrhosis. Liver biopsy in
1999 showed hemosiderotic nodules (Fig. 2). Because of the
enhancement of jaundice and appearance of ascites, he was
hospitalized in July 2001. He was HBeAg positive and his
serumHBVDNAlevelwas7.6 LGE/ml.Serumiron,UIBC,
and ferritin levels were 167 lg/dl, 7 lg/dl, and 291.7 ng/ml,
respectively. Abdominal CT scan showed diffuse high-den-
sitynodules andmagneticresonance imaging(MRI)showed
multiple nodules, with markedly low-signal intensities by
T1-weighted gradient echo MRI and with longer TE (echo
time) revealing hemosiderotic nodules [16] (Fig. 3a, b: left).
Changesinlaboratoryﬁndings(Fig. 4a),serumferritinlevels
(Fig. 4b), and iron and UIBC levels (Fig. 4c) are shown.
HBVDNAbecameundetectable6 monthsaftertheinitiation
of therapy and remained undetectable thereafter. Break-
through hepatitis due to a YMDD mutant strain was not
observed. Serum ALT, albumin, and jaundice levels
improved gradually. Along with these ﬁndings, serum iron
and ferritin levels decreased gradually and UIBC levels
increased. CT scanning, 30 months after the initiation of
LAM, showed a marked reduction of high-density nodules
and MRI, 36 months after, also showed a reduction in the
number of hemosiderotic nodules (Fig. 3a, b: right). These
ﬁndings revealed a marked improvement of hepatic hemo-
siderosis with LAM treatment.
We looked for mutations of the HFE gene using DNA
from white blood cells after informed consent was obtained
[17]. We could not detect either the C282Y or the H63D
mutations by PCR-RFLP analysis (data not shown).
Discussion
A large number of studies have explored the relationship
between iron and chronic viral hepatitis [11]. Several
(a)
(b)
(c)
Fig. 1 Changes of serum ALT (a), HBV DNA (b), and ferritin levels
before and at 6 and 12 months after LAM treatment. Open and closed
circles indicate the values for YMDD mutant (-) and (+),
respectively. All three values were signiﬁcantly higher in the patients
with mutants than those without mutants at 12 months after the
treatment (**P\0.01). Serum ferritin levels decreased signiﬁcantly
12 months after treatment in the patients without mutants
Table 2 Changes of serum iron and UIBC levels in the patients
treated with LAM. Mean SD values are shown
Before 6 M 12 M
Fe (lg/dl)
Mutant(-) 162 ± 62 130 ± 51 137 ± 57
Mutant(+) 127 ± 50 136 ± 30 125 ± 38
UIBC (lg/dl)
Mutant(-) 188 ± 93* 215 ± 68 221 ± 70*
Mutant(+) 187 ± 48 173 ± 72 184 ± 63
* P\0.05
Fig. 2 Liver biopsy obtained in July 1999. Perl’s Prussian blue
staining demonstrated that hepatocytes were stained intensely and
formed hemosiderotic nodules
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123investigators have noted a high prevalence of elevated
serum iron transferrin and ferritin levels in subjects with
chronic viral hepatitis [18, 19]. It is implied that active
HBV replication increases ferritin synthesis, resulting in
increased liver iron storage [20, 21]. In addition, elevated
serum ferritin levels are caused by active hepatitis, perhaps
reﬂecting a release of ferritin and ALT from damaged
hepatocytes and the upregulation of serum ferritin levels
may be a part of the inﬂammatory response [11]. This may
imply that serum ferritin levels are directly correlated with
ALT levels [18]. Successful antiviral treatment, resulting in
the reduction of virus replication, may normalize the serum
ALT levels and reduce the ferritin levels. Liu et al. [15]
showed that LAM could reduce the serum ferritin levels in
patients with chronic HBV infection. The effect was more
signiﬁcant in patients exhibiting virological, serological,
Fig. 3 (a) Abdominal CT scan showing a cirrhotic liver with severe
atrophy and diffuse high-density nodules (left) that were considered to
be hemosiderotic nodules, with a marked improvement of these
ﬁndings 30 months after the initiation of LAM therapy (right).
Hemosiderotic nodules were revealed as multiple hepatic nodules
with markedly low-signal intensities (arrow) by T1-weighted gradient
echo MRI with longer TE (echo time) (b)[ 16]. Their number
relatively decreased 36 months after the initiation of therapy (right)
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123and biochemical responses. However, they did not address
the relationship between the iron-decreasing effect of LAM
and the emergence of YMDD mutants.
In this study, 23 of 30 (77%) patients had undetectable
serum HBV DNA levels after 12 months of LAM treat-
ment, whereas seven (23%) had detectable levels of HBV
DNA. Because YMDD mutants were detected only in
seven patients who were positive for HBV DNA, there was
a clear correlation of positivity of HBV DNA with the
emergence of mutants. Serum ALT levels were signiﬁ-
cantly lower in patients who had undetectable HBV DNA.
Interestingly, serum ferritin levels were signiﬁcantly lower
in patients who had lower ALT and undetectable levels of
HBV DNA (i.e., those with mutants) than those with higher
ALT and HBV DNA levels (i.e., those without mutants).
These results show that the ferritin-decreasing effect of
LAM was evident in patients exhibiting virological and
biochemical responses [15] and this effect was diminished
when YMDD mutants emerged and ALT and HBV DNA
levels became elevated. This reﬂects the clear correlation
between replication of HBV and ﬂare up of hepatitis and
the elevation of ferritin levels. Thus, serum ferritin levels
may correlate clearly with the activity of hepatitis [18].
Successful long-term LAM therapy may maintain this
improvement as long as an emergence of mutants does not
occur.
In addition to the ferritin-decreasing effect of LAM in the
cohort of 30 patients, we present a single case of a patient
with end-stage liver cirrhosis type B who was treated with
LAM. Severe iron overload is seen frequently in patients
with end-stage liver cirrhosis [12, 13]. This might be the
case with this patient whose iron accumulation in the liver
may have been the consequence of long-standing inﬂam-
mation due to active replication of HBV. Successful LAM
therapy brought a long-term suppression of HBV replica-
tion and an improvement of liver function. Both effects
were considered to result in a dramatic reduction in the iron
accumulation that had occurred in the liver.
Although serum ferritin levels decreased signiﬁcantly
with the reduction of serum HBV DNA and ALT levels, we
could not observe dramatic changes of serum iron and
UIBC levels in 30 patients, such as was seen in the repre-
sentative patient.Serum UIBClevelsincreased signiﬁcantly
after 12 months of treatment only in the patients without
mutants (Table 2). The progress of liver damage and
accumulation of iron were not as severe in 30 patients as in
the particular case, so that the iron-decreasing effect of
LAM was more marginal than that observed in the case.
There is a close relationship between iron accumulation
and hepatocarcinogenesis [22]. A direct effect of iron on
cellular proliferation and an indirect effect on the formation
of reactive oxygen species within the liver have been
considered [22]. A positive effect of phlebotomy on
chronic hepatitis C infection has also been conﬁrmed [23].
Long-term phlebotomy with a low-iron diet lowers the risk
of development of HCC in chronic hepatitis C infection
[24]. Recently, LAM has been shown to reduce the inci-
dence of HCC in patients with chronic HBV infection [25].
In summary, this preliminary study shows that effective
antiviral treatment with LAM may reduce iron accumula-
tion in the liver. Successive anti-HBV treatment possibly
might lower the risk of HCC by both the suppression of
Fig. 4 Changes of laboratory ﬁndings before and after the initiation
of LAM therapy. Left and right vertical axes show the ALT, serum
albumin, and bilirubin values, respectively. There was an ameliora-
tion of liver function, that is, a decrease of ALT and bilirubin levels
and increase of albumin levels after the start of LAM (a). A marked
reduction of serum ferritin levels (b), as well as a reduction of serum
iron and increase of UIBC levels, was observed after the start of LAM
treatment
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123inﬂammation due to HBV replication and the iron-reducing
effect. This hypothesis should be tested in the future large-
scale study.
Acknowledgment We thank Ms. Naomi Cho for her technical
assistance.
References
1. Sherlock S. Viruses and hepatocellular carcinoma. Gut 1994;35:
828–832
2. Omata M, Yoshida H. Prevention and treatment of hepatocellular
carcinoma. Liver Transpl 2004;10(2 Suppl 1):S111–S114
3. Chu CM, Liaw YF. Hepatitis B virus-related cirrhosis: natural
history and treatment. Semin Liver Dis 2006;26(2):142–152
4. Hoofnagle JH, di Bisceglie AM. The treatment of chronic viral
hepatitis. N Engl J Med 1997;336:347–356
5. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis
B: 2000–summary of a workshop. Gastroenterology 2001;120:
1828–1853
6. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhi-
bition of the replication of hepatitis B virus in vitro by 20,3 0-
dideoxy–30-thiacytidine and related analogues. Proc Natl Acad
Sci U S A 1991;88:8495–8499
7. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C,
Rubin M. A preliminary trial of lamivudine for chronic hepatitis
B infection. N Engl J Med 1995;333:1657–1661
8. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al.
A one-year trial of lamivudine for chronic hepatitis B. Asia
Hepatitis Lamivudine Study Group. N Engl J Med 1998;339(2):
61–68
9. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters
KA, Tyrrell DL, et al. Identiﬁcation and characterization of
mutations in hepatitis B virus resistant to lamivudine. Lamivu-
dine Clinical Investigation Group. Hepatology 1998;27:
1670–1677
10. Buti M, Jardi R, Cotrina M, Rodriguez-Frias F, Esteban R,
Guardia J. Transient emergence of hepatitis B variants in a
patient with chronic hepatitis B resistant to lamivudine. J Hepatol
1998;28:510–513
11. Bonkovsky HL, Banner BF, Rothman AL. Iron and chronic viral
hepatitis. Hepatology 1997;25:759–768
12. Ludwig J, Hashimoto E, Porayko MK, Moyer TP, Baldus WP.
Hemosiderosis in cirrhosis: a study of 447 native livers. Gastro-
enterology 1997;112:882–888
13. Deugnier Y, Turlin B, le Quilleuc D, Moirand R, Loreal O,
Messner M, et al. A reappraisal of hepatic siderosis in patients
with end-stage cirrhosis: practical implications for the diagnosis
of hemochromatosis. Am J Surg Pathol 1997;21:669–675
14. Kageyama F, Kobayashi Y, Kawasaki T, Toyokuni S, Uchida K,
Nakamura H. Successful interferon therapy reverses enhanced
hepatic iron accumulation and lipid peroxidation in chronic
hepatitis C. Am J Gastroenterol 2000;95:1041–1050
15. Liu ZW, Han QY, Zhang N, Kang W. Sequential changes of
serum ferritin levels and their clinical signiﬁcance in lamivudine-
treated patients with chronic viral hepatitis B. World J Gastro-
enterol 2004;10:972–976
16. Ito K, Mitchell DG. Imaging diagnosis of cirrhosis and chronic
hepatitis. Intervirology 2004;47:134–143
17. Shiono Y, Ikeda R, Hayashi H, Wakusawa S, Sanae F, Takikawa
T, et al. C282Y and H63D mutations in the HFE gene have no
effect on iron overload disorders in Japan. Intern Med 2001;40:
852–856
18. Di Bisceglie AM, Axiotis CA, Hoofnagle JH, Bacon BR. Mea-
surements of iron status in patients with chronic hepatitis.
Gastroenterology 1992;102:2108–2113
19. Arber N, Konikoff FM, Moshkowitz M, Baratz M, Hallak A,
Santo M, et al. Increased serum iron and iron saturation without
liver iron accumulation distinguish chronic hepatitis C from other
chronic liver diseases. Dig Dis Sci 1994;39:2656–2659
20. Lustbader ED, Hann HW, Blumberg BS. Serum ferritin as a
predictor of host response to hepatitis B virus infection. Science
1983;220:423–425
21. Cohen C, Berson SD, Shulman G, Budgeon LR. Liver iron stores
and hepatitis B antigen status. Cancer 1985;56:2201–2204
22. Kowdley KV. Iron, hemochromatosis, and hepatocellular carci-
noma. Gastroenterology 2004;127:S79–S86
23. Heathcote EJ. Prevention of hepatitis C virus-related hepatocel-
lular carcinoma. Gastroenterology 2004;127(5 Suppl 1):
S294–S302
24. Kato J, Miyanishi K, Kobune M, Nakamura T, Takada K,
Takimoto R, et al. Long-term phlebotomy with low-iron diet
therapy lowers risk of development of hepatocellular carcinoma
from chronic hepatitis C. J Gastroenterol 2007;42:830–836
25. Matsumoto A, Tanaka E, Rokuhara A, Kiyosawa K, Kumada H,
Omata M, et al. Efﬁcacy of lamivudine for preventing hepato-
cellular carcinoma in chronic hepatitis B: a multicenter
retrospective study of 2795 patients. Hepatol Res 2005;32:
173–184
26. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ.
Classiﬁcation of chronic hepatitis: diagnosis, grading and staging.
Hepatology 1994;19:1513–1520
Hepatol Int (2008) 2:382–387 387
123